Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer

A. C. Pant, T. Diaz-Montes, E. Tanner, S. Ahmad, R. L. Giuntoli, R. W. Holloway, R. E. Bristow

Research output: Contribution to journalArticle

Abstract

The aim of this study was to determine if in vitro extreme drug resistance (EDR) to platinum and/or taxane chemotherapy was predictive of patient response to intraperitoneal (I.P.) chemotherapy in patients with stage III or recurrent epithelial ovarian cancer (EOC). Fifty-six patients were retrospectively identified who underwent optimal cytoreductive surgery for primary or recurrent EOC and then received at least three cycles of either intravenous (I.V.) or I.P. chemotherapy with platinum and paclitaxel-based chemotherapy. EDR to platinum and/or paclitaxel was determined using a commercially available assay (Oncotech, Inc., Tustin, CA). The primary outcome measure was progression-free survival (PFS). Twenty-nine (52%) patients received I.P. chemotherapy and 27 (48%) received I.V. chemotherapy. The patients were well matched in terms of age, stage, grade and histology. Ten (35%) patients in the I.P. arm and ten (37%) patients in the I.V. arm showed EDR to either platinum and/or paclitaxel. Median PFS for all I.P. chemotherapy patients was 23 months, compared with 13 months for those receiving I.V. chemotherapy (P = 0.04). Patients with EDR to platinum and/or taxane who underwent I.V. chemotherapy had a median PFS of 13.5 months, whereas those who underwent I.P. treatment had a median PFS of 15 months (P = 0.69). Median overall survival had not been reached at the time of analysis. No significant difference in PFS was noted between patients who underwent I.P. and those who underwent I.V. chemotherapy when EDR was predicted to either platinum or paclitaxel or both. These data suggest that the decision to offer I.P. chemotherapy, with the attendant increase in morbidity, in the setting of EDR to platinum and/or taxane chemotherapy, may not be beneficial. Prospective studies, preferably analyzing platinum or taxane EDR individually, are required to validate these observations.

Original languageEnglish (US)
Pages (from-to)270-274
Number of pages5
JournalJournal of Chemotherapy
Volume22
Issue number4
StatePublished - Aug 2010

Fingerprint

Drug Resistance
Ovarian Neoplasms
Disease-Free Survival
Platinum
Drug Therapy
Paclitaxel
Histology
Outcome Assessment (Health Care)
Prospective Studies
Morbidity
Survival

Keywords

  • Extreme drug resistance
  • Intraperitoneal chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Cite this

Pant, A. C., Diaz-Montes, T., Tanner, E., Ahmad, S., Giuntoli, R. L., Holloway, R. W., & Bristow, R. E. (2010). Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer. Journal of Chemotherapy, 22(4), 270-274.

Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer. / Pant, A. C.; Diaz-Montes, T.; Tanner, E.; Ahmad, S.; Giuntoli, R. L.; Holloway, R. W.; Bristow, R. E.

In: Journal of Chemotherapy, Vol. 22, No. 4, 08.2010, p. 270-274.

Research output: Contribution to journalArticle

Pant, AC, Diaz-Montes, T, Tanner, E, Ahmad, S, Giuntoli, RL, Holloway, RW & Bristow, RE 2010, 'Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer', Journal of Chemotherapy, vol. 22, no. 4, pp. 270-274.
Pant, A. C. ; Diaz-Montes, T. ; Tanner, E. ; Ahmad, S. ; Giuntoli, R. L. ; Holloway, R. W. ; Bristow, R. E. / Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer. In: Journal of Chemotherapy. 2010 ; Vol. 22, No. 4. pp. 270-274.
@article{433b4ae934c64fa5857a3c6de49db720,
title = "Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer",
abstract = "The aim of this study was to determine if in vitro extreme drug resistance (EDR) to platinum and/or taxane chemotherapy was predictive of patient response to intraperitoneal (I.P.) chemotherapy in patients with stage III or recurrent epithelial ovarian cancer (EOC). Fifty-six patients were retrospectively identified who underwent optimal cytoreductive surgery for primary or recurrent EOC and then received at least three cycles of either intravenous (I.V.) or I.P. chemotherapy with platinum and paclitaxel-based chemotherapy. EDR to platinum and/or paclitaxel was determined using a commercially available assay (Oncotech, Inc., Tustin, CA). The primary outcome measure was progression-free survival (PFS). Twenty-nine (52{\%}) patients received I.P. chemotherapy and 27 (48{\%}) received I.V. chemotherapy. The patients were well matched in terms of age, stage, grade and histology. Ten (35{\%}) patients in the I.P. arm and ten (37{\%}) patients in the I.V. arm showed EDR to either platinum and/or paclitaxel. Median PFS for all I.P. chemotherapy patients was 23 months, compared with 13 months for those receiving I.V. chemotherapy (P = 0.04). Patients with EDR to platinum and/or taxane who underwent I.V. chemotherapy had a median PFS of 13.5 months, whereas those who underwent I.P. treatment had a median PFS of 15 months (P = 0.69). Median overall survival had not been reached at the time of analysis. No significant difference in PFS was noted between patients who underwent I.P. and those who underwent I.V. chemotherapy when EDR was predicted to either platinum or paclitaxel or both. These data suggest that the decision to offer I.P. chemotherapy, with the attendant increase in morbidity, in the setting of EDR to platinum and/or taxane chemotherapy, may not be beneficial. Prospective studies, preferably analyzing platinum or taxane EDR individually, are required to validate these observations.",
keywords = "Extreme drug resistance, Intraperitoneal chemotherapy, Ovarian cancer",
author = "Pant, {A. C.} and T. Diaz-Montes and E. Tanner and S. Ahmad and Giuntoli, {R. L.} and Holloway, {R. W.} and Bristow, {R. E.}",
year = "2010",
month = "8",
language = "English (US)",
volume = "22",
pages = "270--274",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Correlation of extreme drug resistance assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer

AU - Pant, A. C.

AU - Diaz-Montes, T.

AU - Tanner, E.

AU - Ahmad, S.

AU - Giuntoli, R. L.

AU - Holloway, R. W.

AU - Bristow, R. E.

PY - 2010/8

Y1 - 2010/8

N2 - The aim of this study was to determine if in vitro extreme drug resistance (EDR) to platinum and/or taxane chemotherapy was predictive of patient response to intraperitoneal (I.P.) chemotherapy in patients with stage III or recurrent epithelial ovarian cancer (EOC). Fifty-six patients were retrospectively identified who underwent optimal cytoreductive surgery for primary or recurrent EOC and then received at least three cycles of either intravenous (I.V.) or I.P. chemotherapy with platinum and paclitaxel-based chemotherapy. EDR to platinum and/or paclitaxel was determined using a commercially available assay (Oncotech, Inc., Tustin, CA). The primary outcome measure was progression-free survival (PFS). Twenty-nine (52%) patients received I.P. chemotherapy and 27 (48%) received I.V. chemotherapy. The patients were well matched in terms of age, stage, grade and histology. Ten (35%) patients in the I.P. arm and ten (37%) patients in the I.V. arm showed EDR to either platinum and/or paclitaxel. Median PFS for all I.P. chemotherapy patients was 23 months, compared with 13 months for those receiving I.V. chemotherapy (P = 0.04). Patients with EDR to platinum and/or taxane who underwent I.V. chemotherapy had a median PFS of 13.5 months, whereas those who underwent I.P. treatment had a median PFS of 15 months (P = 0.69). Median overall survival had not been reached at the time of analysis. No significant difference in PFS was noted between patients who underwent I.P. and those who underwent I.V. chemotherapy when EDR was predicted to either platinum or paclitaxel or both. These data suggest that the decision to offer I.P. chemotherapy, with the attendant increase in morbidity, in the setting of EDR to platinum and/or taxane chemotherapy, may not be beneficial. Prospective studies, preferably analyzing platinum or taxane EDR individually, are required to validate these observations.

AB - The aim of this study was to determine if in vitro extreme drug resistance (EDR) to platinum and/or taxane chemotherapy was predictive of patient response to intraperitoneal (I.P.) chemotherapy in patients with stage III or recurrent epithelial ovarian cancer (EOC). Fifty-six patients were retrospectively identified who underwent optimal cytoreductive surgery for primary or recurrent EOC and then received at least three cycles of either intravenous (I.V.) or I.P. chemotherapy with platinum and paclitaxel-based chemotherapy. EDR to platinum and/or paclitaxel was determined using a commercially available assay (Oncotech, Inc., Tustin, CA). The primary outcome measure was progression-free survival (PFS). Twenty-nine (52%) patients received I.P. chemotherapy and 27 (48%) received I.V. chemotherapy. The patients were well matched in terms of age, stage, grade and histology. Ten (35%) patients in the I.P. arm and ten (37%) patients in the I.V. arm showed EDR to either platinum and/or paclitaxel. Median PFS for all I.P. chemotherapy patients was 23 months, compared with 13 months for those receiving I.V. chemotherapy (P = 0.04). Patients with EDR to platinum and/or taxane who underwent I.V. chemotherapy had a median PFS of 13.5 months, whereas those who underwent I.P. treatment had a median PFS of 15 months (P = 0.69). Median overall survival had not been reached at the time of analysis. No significant difference in PFS was noted between patients who underwent I.P. and those who underwent I.V. chemotherapy when EDR was predicted to either platinum or paclitaxel or both. These data suggest that the decision to offer I.P. chemotherapy, with the attendant increase in morbidity, in the setting of EDR to platinum and/or taxane chemotherapy, may not be beneficial. Prospective studies, preferably analyzing platinum or taxane EDR individually, are required to validate these observations.

KW - Extreme drug resistance

KW - Intraperitoneal chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=78650253210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650253210&partnerID=8YFLogxK

M3 - Article

C2 - 20685633

AN - SCOPUS:78650253210

VL - 22

SP - 270

EP - 274

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -